An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

Completed · Phase 2

Conditions studied: Acne Vulgaris

In brief

This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris. Adrenal suppression effects and systemic safety are an important safety concern. The current study is designed to investigate these potential concerns under maximal use conditions.

Key facts

Study ID

NCT02720627

Run by

Cassiopea SpA

People needed

27

Starts

2016-10-28

Expected to finish

2018-03-21

Last updated by the study team

2020-11-20

Who can join

Age: 9 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide written informed consent for the patient.
• Patient has moderate to severe facial acne vulgaris as determined by the Investigator and obvious acne on the trunk (i.e., shoulders, upper chest, and/or back).
• Females of childbearing potential must be using highly effective birth control methods with a negative urine pregnancy test (UPT) at study start.
• Patient must be in general good health with normal renal function and no clinically relevant abnormalities present at study start.
• Patient and parent/guardian are able to communicate with the staff and are willing to comply with study instructions, reside at and/or return to the clinic for required visits.

You may not qualify if…

• Patient is pregnant, lactating, or is planning to become pregnant during the study.
• Patient has a Body Mass Index (BMI) for age percentile > 95%.
• Patient has any skin or medical condition, including facial hair that could interfere with the evaluation of the test article or requires the use of interfering topical or systemic therapy.
• Patient has received an investigational drug or been treated with an investigational device within 30 days prior to study start.
• Patient is currently enrolled in an investigational drug or device study.
• Patient has any condition which, in the investigator's opinion, would make it unsafe for the patient to participate in this research study.
• Patient has known allergy or sensitivity to CB-03-01 or any of its ingredients
• Patient has participated in a previous CB-03-01 study.

Where it is running

• Site 103 — Fort Smith, Arkansas, United States
• Site 101 — San Diego, California, United States
• Site 102 — Houston, Texas, United States
• Site 4814 — Częstochowa, Poland
• Site 4811 — Katowice, Poland
• Site 4813 — Krakow, Poland
• Site 4815 — Krakow, Poland
• Site 4816 — Rzeszów, Poland
• Site 4812 — Szczecin, Poland
• Site 4817 — Tarnów, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.